Lueken, U
Kuhn, M
Yang, Y
Straube, B
Kircher, T
Wittchen, H-U
Pfleiderer, B
Arolt, V
Wittmann, A
Ströhle, A
Weber, H
Reif, A
Domschke, K
Deckert, J
Lonsdorf, T B
Article History
Received: 15 February 2017
Revised: 7 June 2017
Accepted: 4 July 2017
First Online: 5 September 2017
Competing interests
: TK received fees for educational programs from Janssen-Cilag, Eli Lilly, Servier, Lundbeck, Bristol Myers Squibb, Pfizer, and Astra-Zeneca; travel support/sponsorship for congresses from Servier; speaker’s honoraria from Janssen-Cilag; and research grants from Pfizer and Lundbeck. H-UW has been member of advisory boards of several pharmaceutical companies. He received travel reimbursements and research grant support from Essex Pharma, Sanofi, Pfizer, Organon, Servier, Novartis, Lundbeck, Glaxo Smith Kline. VA is member of advisory boards and/or gave presentations for the following companies: Astra-Zeneca, Janssen-Organon, Lilly, Lundbeck, Servier, Pfizer, and Wyeth. He also received research grants from Astra-Zeneca, Lundbeck, and Servier. He chaired the committee for the ‘Wyeth Research Award Depression and Anxiety’. AS received research funding from the German Federal Ministry of Education and Research, the European Commission (FP6) and Lundbeck, and speaker honoraria from Astra-Zeneca, Boehringer Ingelheim, Eli Lilly & Co, Lundbeck, Pfizer, Wyeth, and UCB. Educational grants were given by the Stifterverband für die Deutsche Wissenschaft, the Berlin Brandenburgische Akademie der Wissenschaften, the Boehringer Ingelheim Fonds and the Eli Lilly International Foundation. AR has received a research grant from Medice, and speaker’s honoraria from Medice and neuraxpharm. The remaining authors declare no conflict of interest.